150 related articles for article (PubMed ID: 28621612)
41. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
[TBL] [Abstract][Full Text] [Related]
42. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
43. Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population.
Wang LZ; Sato K; Tsuchiya N; Yu JG; Ohyama C; Satoh S; Habuchi T; Ogawa O; Kato T
Cancer Lett; 2003 Dec; 202(1):53-9. PubMed ID: 14643026
[TBL] [Abstract][Full Text] [Related]
44. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer.
Huang SP; Wu WJ; Chang WS; Wu MT; Chen YY; Chen YJ; Yu CC; Wu TT; Lee YH; Huang JK; Huang CH
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2217-24. PubMed ID: 15598783
[TBL] [Abstract][Full Text] [Related]
45. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
[TBL] [Abstract][Full Text] [Related]
46. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
[TBL] [Abstract][Full Text] [Related]
47. Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancer.
Kucerova R; Bienova M; Kral M; Bouchal J; Trtkova KS; Burdova A; Student V; Kolar Z
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):91-6. PubMed ID: 24665929
[TBL] [Abstract][Full Text] [Related]
48. Cyclooxygenase 2 (rs2745557) Polymorphism and the Susceptibility to Benign Prostate Hyperplasia and Prostate Cancer in Egyptians.
Fawzy MS; Elfayoumi AR; Mohamed RH; Fatah IRA; Saadawy SF
Biochem Genet; 2016 Jun; 54(3):326-336. PubMed ID: 26920155
[TBL] [Abstract][Full Text] [Related]
49. Association of benign prostate hyperplasia with polymorphisms in VDR, CYP17, and SRD5A2 genes among Lebanese men.
El Ezzi AA; Zaidan WR; El-Saidi MA; Al-Ahmadieh N; Mortenson JB; Kuddus RH
Asian Pac J Cancer Prev; 2014; 15(3):1255-62. PubMed ID: 24606449
[TBL] [Abstract][Full Text] [Related]
50. Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men.
Han Z; Zhang L; Zhu R; Luo L; Zhu M; Fan L; Wang G
Medicine (Baltimore); 2017 Mar; 96(13):e6473. PubMed ID: 28353585
[TBL] [Abstract][Full Text] [Related]
51. Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia.
Yoo KH; Kim SK; Chung JH; Chang SG
Asian J Androl; 2010 Sep; 12(5):690-6. PubMed ID: 20562898
[TBL] [Abstract][Full Text] [Related]
52. Polymorphisms of MLH1 in benign prostatic hyperplasia and sporadic prostate cancer.
Tanaka Y; Zaman MS; Majid S; Liu J; Kawakami K; Shiina H; Tokizane T; Dahiya AV; Sen S; Nakajima K
Biochem Biophys Res Commun; 2009 Jun; 383(4):440-4. PubMed ID: 19364498
[TBL] [Abstract][Full Text] [Related]
53. The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH).
Chen ZP; Yan Y; Chen CJ; Li M; Chen C; Zhao SC; Song T; Liu T; Zou CH; Xu Q; Li X
Andrology; 2018 Jul; 6(4):568-578. PubMed ID: 29873201
[TBL] [Abstract][Full Text] [Related]
54. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M;
J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633
[TBL] [Abstract][Full Text] [Related]
55. Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.
Izmirli M; Arikan B; Bayazit Y; Alptekin D
Asian Pac J Cancer Prev; 2011; 12(3):731-3. PubMed ID: 21627373
[TBL] [Abstract][Full Text] [Related]
56. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men.
Ho CK; Anwar S; Nanda J; Habib FK
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):94-6. PubMed ID: 19918264
[TBL] [Abstract][Full Text] [Related]
57. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia.
Tayeb MT; Clark C; Haites NE; Sharp L; Murray GI; McLeod HL
Saudi Med J; 2004 Apr; 25(4):447-51. PubMed ID: 15083213
[TBL] [Abstract][Full Text] [Related]
58. A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia.
Basu S; Majumder S; Bhowal A; Ghosh A; Naskar S; Nandy S; Mukherjee S; Sinha RK; Basu K; Karmakar D; Banerjee S; Sengupta S
PLoS One; 2015; 10(5):e0125560. PubMed ID: 25938433
[TBL] [Abstract][Full Text] [Related]
59. Genetic Polymorphism of MMP2 Gene and Susceptibility to Prostate Cancer.
Adabi Z; Mohsen Ziaei SA; Imani M; Samzadeh M; Narouie B; Jamaldini SH; Afshari M; Safavi M; Roshandel MR; Hasanzad M
Arch Med Res; 2015 Oct; 46(7):546-50. PubMed ID: 26319608
[TBL] [Abstract][Full Text] [Related]
60. Mitochondrial D-Loop polymorphism and microsatellite instability in prostate cancer and benign hyperplasia patients.
Ashtiani ZO; Heidari M; Hasheminasab SM; Ayati M; Rakhshani N
Asian Pac J Cancer Prev; 2012; 13(8):3863-8. PubMed ID: 23098484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
